267 related articles for article (PubMed ID: 23249728)
21. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms: a systematic review and meta-analysis.
Shan D; Zou L; Liu X; Shen Y; Cai Y; Zhang J
Am J Obstet Gynecol; 2020 Jun; 222(6):564-579.e12. PubMed ID: 31870736
[TBL] [Abstract][Full Text] [Related]
22. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment.
Rapkin AJ
Am J Obstet Gynecol; 2007 Feb; 196(2):97-106. PubMed ID: 17306645
[TBL] [Abstract][Full Text] [Related]
23. Estradiol/progesterone (Bijuva) for menopausal vasomotor symptoms.
Med Lett Drugs Ther; 2019 Jul; 61(1575):99-101. PubMed ID: 31381541
[No Abstract] [Full Text] [Related]
24. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks.
Moskowitz D
Altern Med Rev; 2006 Sep; 11(3):208-23. PubMed ID: 17217322
[TBL] [Abstract][Full Text] [Related]
25. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of progestin-only treatment for the management of menopausal symptoms: a systematic review.
Dolitsky SN; Cordeiro Mitchell CN; Stadler SS; Segars JH
Menopause; 2020 Nov; 28(2):217-224. PubMed ID: 33109992
[TBL] [Abstract][Full Text] [Related]
27. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women.
Wren BG; Champion SM; Willetts K; Manga RZ; Eden JA
Menopause; 2003; 10(1):13-8. PubMed ID: 12544672
[TBL] [Abstract][Full Text] [Related]
28. Management of Hormone Deprivation Symptoms After Cancer.
Faubion SS; Loprinzi CL; Ruddy KJ
Mayo Clin Proc; 2016 Aug; 91(8):1133-46. PubMed ID: 27492917
[TBL] [Abstract][Full Text] [Related]
29. An overview of menopause associated vasomotor symptoms and options available in its management.
Okeke TC; Ezenyeaku CC; Ikeako LC; Agu PU
Niger J Med; 2013; 22(1):7-14. PubMed ID: 23441513
[TBL] [Abstract][Full Text] [Related]
30. Systematic review of progesterone use by midlife and menopausal women.
Spark MJ; Willis J
Maturitas; 2012 Jul; 72(3):192-202. PubMed ID: 22541358
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
[TBL] [Abstract][Full Text] [Related]
32. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.
Archer DF; Dupont CM; Constantine GD; Pickar JH; Olivier S;
Am J Obstet Gynecol; 2009 Mar; 200(3):238.e1-238.e10. PubMed ID: 19167693
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of compounded bioidentical hormone replacement therapy.
Vigesaa KA; Downhour NP; Chui MA; Cappellini L; Musil JD; McCallian DJ
Int J Pharm Compd; 2004; 8(4):313-9. PubMed ID: 23924704
[TBL] [Abstract][Full Text] [Related]
34. Vasomotor menopausal symptoms and risk of coronary heart disease: a life course perspective.
Hardy R
Menopause; 2011 Feb; 18(2):127-8. PubMed ID: 21135711
[No Abstract] [Full Text] [Related]
35. Micronized progesterone, progestins, and menopause hormone therapy.
Hipolito Rodrigues MA; Gompel A
Women Health; 2021 Jan; 61(1):3-14. PubMed ID: 32957843
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
37. Bioidentical hormone therapy in menopause: relevance in dermatology.
Borda LJ; Wong LL; Tosti A
Dermatol Online J; 2019 Jan; 25(1):. PubMed ID: 30710894
[TBL] [Abstract][Full Text] [Related]
38. New pharmacological therapies for vasomotor symptom management: focus on bazedoxifene/conjugated estrogens and paroxetine mesylate.
Carris N; Kutner S; Reilly-Rogers S
Ann Pharmacother; 2014 Oct; 48(10):1343-9. PubMed ID: 25028744
[TBL] [Abstract][Full Text] [Related]
39. Estradiol gel 0.1% relieves vasomotor symptoms independent of age, ovarian status, or uterine status.
Hedrick RE; Ackerman RT; Koltun WD; Halvorsen MB
Menopause; 2010; 17(6):1167-73. PubMed ID: 20720511
[TBL] [Abstract][Full Text] [Related]
40. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.
Mirkin S; Amadio JM; Bernick BA; Pickar JH; Archer DF
Maturitas; 2015 May; 81(1):28-35. PubMed ID: 25835751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
